Viridian raises ~$150M in stock offering, reports $477M cash, outlines VRDN-003/001 trial timelines

Viridian Therapeutics, Inc.\DE

Raised ~$150M gross from 7.14M shares at $21.00; underwriters have 30-day option for 1.07M additional shares.
Preliminary cash and investments of $477.4M as of Dec 31, 2023; combined with offering expected to fund ops into H2 2026.
VRDN-003: global pivotal trials in active and chronic TED planned to start mid-2024 pending regulatory alignment.
VRDN-001: THRIVE Phase 3 topline in active TED expected mid-2024; THRIVE-2 chronic TED topline by year-end 2024.
BLA package for VRDN-001 to include THRIVE, THRIVE-2 studies and safety database of ~300 treated patients.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viridian Therapeutics, Inc.\DE entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC valued at approximately $150.0 million (effective 2024-01-17).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC and Leerink Partners LLC
Value: approximately $150.0 million
Effective: 2024-01-17

Exact text from the filing

On January 17, 2024, Viridian Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (collectively, the “Representatives”) relating to the offer and sale (the “Offering”) of 7,142,858 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a public offering price of $21.00 per share.

View on SEC.gov

235 material agreements filed in the last 30 days. Browse all material agreements →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-24-011355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.